Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Gd-DTPA Labeled Dextran' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Gd-DTPA Labeled Dextran' found in 1 term [] and 1 definition []
1 - 2 (of 2)     
Result Pages : [1]
MRI Resources 
Equipment - RIS - MRI Reimbursement - Guidance - Health - MR Guided Interventions
 
Gd-DTPA Labeled DextranInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name:(Gd-DTPA)n-dextran, central moiety: Gd2+
Gd-DTPA labeled dextran is a substance that has been tested as a blood pool agent (intravascular MRI contrast agent). Dextran is a polysaccharide and has labeled with 15 Gd-DTPA moieties a higher T1 relaxivity than unbound Gd-DTPA, compared with a high safety level.

See also Intravascular Contrast Agents, Blood Pool Agents.
spacer
 
• Share the entry 'Gd-DTPA Labeled Dextran':  Facebook  Twitter  LinkedIn  
 
Further Reading:
  Basics:
Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent: imaging characteristics in normal rat tissues
   by radiology.rsnajnls.org    
MRI Resources 
Service and Support - - Contrast Agents - Spine MRI - Devices - Shoulder MRI
 
Blood Pool AgentsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Blood pool agents (intravascular contrast agents) remain in the blood for a prolonged time compared with conventional contrast agents, which diffuse quickly into the interstitial space. Magnetic resonance angiography (MRA), cardiovascular imaging, or contrast enhanced MRIs are possible over an hour or more. This advantage over conventional MRI contrast media allows also higher resolution MRA of several territories using respiratory or cardiac gating techniques with a single contrast bolus.
Different types of blood pool contrast agents:
Blood pool MRI contrast agents with their longer intravascular circulation can be designed to be targeted to necrotic myocardium, to assess myocardial viability, or tumor directed to provide better diagnostic information for various tumors. A disadvantage of the use of blood pool agents for MRA is that the separation of arteries and veins is more difficult because they are present in both and the overlapping of those vessels is disturbing. This can be solved by e.g. different MIP segmentation algorithms.

See also Necrosis Avid Contrast Agent, Tumor Specific Agents, Feruglose, Gadofosveset Trisodium (Vasovist), Ultrasmall Superparamagnetic Iron Oxide and Contrast Medium.
spacer

• View the DATABASE results for 'Blood Pool Agents' (16).Open this link in a new window


• View the NEWS results for 'Blood Pool Agents' (1).Open this link in a new window.
 
Further Reading:
  Basics:
Ablavar Prescribing Information
   by www.ablavar.com    
Lantheus Medical Imaging, Inc. Launches ABLAVAR™ (Gadofosveset Trisodium), a New Diagnostic Magnetic Resonance Angiography Agent
Wednesday, 20 January 2010   by www.radiopharm.com    
Blood-Pool Imaging Using Technetium-99m-Labeled Liposomes(.pdf)
   by jnm.snmjournals.org    
  News & More:
Multimodal Nanoparticles for Quantitative Imaging(.pdf)
Tuesday, 13 December 2011   by alexandria.tue.nl    
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
MRI Resources 
MRI Training Courses - Brain MRI - Shielding - Functional MRI - Pacemaker - Manufacturers
 
     1 - 2 (of 2)     
Result Pages : [1]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



Next big thing in MRI will be :
AI 
remote operator 
personalized protocols 
helium-free 
molecular MRI 
portable MRI 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 21 November 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]